Infectious Disease Diagnostics Market Scope And Analysis

Report Code : TIPHE100001430
Category : Life Sciences

Status : Published
No. of Pages : 280

Buy Now

Infectious Disease Diagnostics Market Analysis Report 2023 to 2030

Buy Now

Infectious Disease Diagnostics Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 38.37 Billion
Market Size by 2030	US$ 59.95 Billion
Global CAGR (2022 - 2030)	5.7%
Historical Data	2020-2021
Forecast period	2023-2030
Segments Covered	By Product Kits & Reagents Instruments Software & Services By Technology Biosensor-Based Immunodiagnostics Molecular-Based Diagnostic Techniques Clinical Biology By Application Type Laboratory Testing and Point-of-Care Testing By Testing Type Human Testing and Veterinary Testing
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Abbott Laboratories Bruker Corp Cardinal Health F Hoffmann La Roche Ltd Trinity Biotech Plc Danaher Corp Bio Rad Laboratories Inc AccuBioTech Co Ltd ACON Laboratories

Industry Developments and Future Opportunities:

Various initiatives by key players operating in the Infectious Disease Diagnostics Market are listed below:

In January 2023, Trinity Biotech announced a strategic partnership with imaware Inc that combined their built-to-partner digital health platform with Trinity Biotech’s advanced reference laboratory facilities to power the Digital Health Industry with at-home and remote testing programs.
In November 2022, Bio-Rad Laboratories Inc expanded its product portfolio of independent quality controls, including InteliQ and Liquichek compact vials. The products will be used for Abbott's Alinity CI-Series, which is integrated with clinical chemistry and immunoassay testing instruments.
In December 2021, F. Hoffmann-La Roche Ltd launched the first infectious disease tests on the cobas 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark. These include cobas HIV-1, cobas HBV, cobas HCV, cobas HIV-1/HIV-2 Qualitative, and the cobas omni Utility Channel kit. These launches expand the Roche Molecular portfolio offering by providing standardized performance and efficiencies across low, medium, and high-volume molecular laboratory testing needs.

Competitive Landscape and Key Companies:

Abbott Laboratories, Bruker Corp, Cardinal Health, F. Hoffmann-La Roche Ltd, Trinity Biotech Plc, Danaher Corp, Bio-Rad Laboratories Inc, AccuBioTech Co Ltd, ACON Laboratories, and DiaSorin SpA are among the prominent players operating in the infectious disease diagnostics market. These companies focus on new product launches and geographic expansions to meet the growing consumer demand across the world and increase their product range in specialty portfolios. Their global presence allows them to serve a large base of customers, subsequently facilitating market expansion.